title: [Combined modality therapy for a patient with primary adrenal lymphoma].
abstract: A 71-year-old man with malaise, anorexia, and weight loss was referred to our hospital from a clinic. Abdominal computed tomography(CT)revealed bilateral adrenal masses. An ultrasound-guided percutaneous needle biopsy of the adrenal grand indicated diffuse large B-cell lymphoma. A rapid adrenocorticotropic hormone(ACTH)test revealed primary adrenal failure. Rituximab-cyclophosphamide/doxorubicin/vincristine/prednisolone(common name, R-CHOP)therapy accompanied by intrathecal treatment was initiated along with steroid replacement therapy. After the fourth courses, a CT scan showed a reduction of the adrenal masses, and there was no[18F]-fluorodeoxyglucose(FDG)uptake in the adrenal masses. The patient has remained in metabolic complete remission. Subsequently, both adrenal lymphomas were irradiated. The patient has been disease-free for 6 months after the diagnosis of primary adrenal lymphoma. The combined modality of chemoradiation therapy plus intrathecal treatment could be effective for primary adrenal lymphoma with a poor prognosis.
authors.affiliation: Dept. of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine,Steel Memorial Muroran Hospital.
authors.forename: Teppei
authors.initials: T
authors.lastname: Matsuno
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuroda
authors.forename: Wataru
authors.initials: W
authors.lastname: Jomen
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yoshida
authors.forename: Michiko
authors.initials: M
authors.lastname: Yamada
authors.forename: Masanori
authors.initials: M
authors.lastname: Sato
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Abe
authors.forename: Tamaki
authors.initials: T
authors.lastname: Sakurai
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Fujii
authors.forename: Masahiro
authors.initials: M
authors.lastname: Maeda
authors.forename: Miri
authors.initials: M
authors.lastname: Fujita
authors.forename: Kazuo
authors.initials: K
authors.lastname: Nagashima
authors.forename: Shuichi
authors.initials: S
authors.lastname: Nojiri
authors.forename: Yohei
authors.initials: Y
authors.lastname: Arihara
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000473:pathology / Q000628:therapy*; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone